Clinical Trials Logo

Arthritis, Juvenile clinical trials

View clinical trials related to Arthritis, Juvenile.

Filter by:

NCT ID: NCT01667471 Completed - Clinical trials for Juvenile Idiopathic Arthritis

A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study

Start date: January 2012
Phase: Phase 3
Study type: Interventional

This long-term, open-label extension study will evaluate the safety of RoActemra/Actemra (tocilizumab) in patients with polyarticular-course juvenile idiopathic arthritis who completed the WA19977 core study. Patients aged 9-18 years with at least JIA ACR30 clinical response to RoActemra/Actemra in the core study will be eligible to receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks. Anticipated time on study treatment is 104 weeks.

NCT ID: NCT01572896 Completed - Clinical trials for Arthritis, Juvenile Idiopathic

An Internet-based Self-management Program for Adolescents With Arthritis

Start date: April 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to demonstrate the effectiveness of the "Taking Charge: Managing JIA Online" Internet intervention, when compared with an attention (static education only websites) control group in improving pain and HRQL as well as other health outcomes (anxiety, depression, treatment adherence, pain coping, knowledge, and self-efficacy) in adolescents with JIA. The proposed study will enroll and randomize 294 adolescents with JIA attending 10 pediatric rheumatology hospital clinics in the Canada to either the experimental or control groups.

NCT ID: NCT01563185 Completed - Clinical trials for Juvenile Idiopathic Arthritis

Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis

Start date: April 2012
Phase: Phase 4
Study type: Interventional

The primary objective of this Phase 4, multi-center, open-label study is to evaluate the safety and tolerability of DUEXIS in Juvenile Idiopathic Arthritis (JIA) patients aged 10 years to 16 years, 11 months, treated up to 24 weeks. The secondary objectives are to evaluate the PK characteristics of DUEXIS in JIA patients and to evaluate the signs and symptoms of JIA in patients aged 10 years to 16 years, 11 months receiving DUEXIS for up to 24 weeks.

NCT ID: NCT01550003 Completed - Clinical trials for Polyarticular-course Juvenile Idiopathic Arthritis (JIA)

Pediatric Arthritis Study of Certolizumab Pegol

PASCAL
Start date: March 8, 2012
Phase: Phase 3
Study type: Interventional

A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA).

NCT ID: NCT01544114 Completed - Clinical trials for Juvenile Idiopathic Arthritis (JIA)

A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)

Start date: April 2012
Phase: Phase 4
Study type: Interventional

A 6-month study of the safety of VIMOVO in adolescents aged 12 to 16 years with JIA.

NCT ID: NCT01541917 Completed - Clinical trials for Juvenile Idiopathic Arthritis

Efficacy of Web-based Pain Self-management for Adolescents With Juvenile Idiopathic Arthritis

WebSMART
Start date: July 2012
Phase: Phase 3
Study type: Interventional

The purpose of this multi-site randomized clinical trial is to determine if an online coping skills training program will produce superior improvements in pain and health-related quality of life outcomes for adolescents with JIA relative to outcomes attained with reviewing online educational information about JIA.

NCT ID: NCT01513902 Completed - Clinical trials for Juvenile Idiopathic Arthritis

Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA)

Start date: March 2013
Phase: Phase 1
Study type: Interventional

Phase 1 study to describe pharmacokinetics of CP-690,550 in pediatric patients 2 to less than 18 years of age with Juvenile Idiopathic Rheumatoid Arthritis (JIA).

NCT ID: NCT01469897 Completed - Clinical trials for Juvenile Idiopathic Arthritis

Cost of Care for Juvenile Idiopathic Arthritis

Start date: January 2012
Phase: N/A
Study type: Observational

This project seeks to collect data on healthcare utilization and expenditure rates in Juvenile Idiopathic Arthritis (JIA) patients from across the US, correlate these costs with disease activity and outcome measures and determine methods by which to reduce the economic impact while improving outcomes.

NCT ID: NCT01455701 Completed - Clinical trials for Juvenile Idiopathic Arthritis

A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)

Start date: October 26, 2012
Phase: Phase 1
Study type: Interventional

This is a multi-center, open-label single-arm study to investigate the pharmacokinetics and safety of tocilizumab (RoActemra/Actemra) in participants less than 2 years old with active sJIA. Participants will receive tocilizumab infusions every 2 weeks. The anticipated time on study treatment is 12 weeks (Main evaluation period). Participants will have the option to continue tocilizumab treatment until participant reaches 2 years of age or up to one year from baseline, whichever is longer. An optional extension period will follow the main evaluation period.

NCT ID: NCT01412021 Completed - Clinical trials for Arthritis, Juvenile Rheumatoid

Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis

Start date: July 1, 2011
Phase:
Study type: Observational

This study of Humira will be conducted to clarify the following with regard to the treatment of juvenile idiopathic arthritis affecting multiple joints with this drug: - Unknown adverse drug reactions (especially important adverse drug reactions) - Incidence and conditions of occurrence of adverse reactions in the clinical setting - Factors that may affect the safety and effectiveness of Humira